Dr. Pinkal Desai (Weill Cornell Medical College, New York, NY, USA) provides a compelling overview of clinical trials presented in the relapsed/refractory acute myeloid leukaemia (AML) setting at the 66th ASH Annual Meeting & Exposition on 7–10 December 2024 in San Diego, CA, USA. These studies highlight promising developments, focusing on novel therapies and their efficacy in specific patient subgroups. Among the most noteworthy are findings on the IRAK4 inhibitor mivobsertib (CA-4948) and an all-oral triplet regimen combining revumenib, decitabine, cedazuridine, and venetoclax. These innovations demonstrate encouraging response rates, particularly in FLT3-mutated and KMT2A/NPM1-mutated AML, offering new hope for patients with limited treatment options. Dr. Desai emphasizes the potential for these therapies in re-shaping the standard-of-care and underscores the importance of further research to refine their application across diverse patient populations.
View more from Dr Desai in acute myeloid leukaemia
Disclosures: Pinkal Desai has received grant/research support from: Kura Oncology, Janssen Research and BMS. she has been a member of the advisory board for: BMS, Kura Oncology, Syndax, Servier and Abbvie. She has received other financial or material support from Genentech/Roche.
This content has been developed independently by Touch Medical Media for touchHAEMATOLOGY. It is not affiliated with the American Society of Hematology (ASH). Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
